Prescription drug · NDA
Synarel (Nafarelin acetate) NDC 0025-0166
Nafarelin acetate 2 mg/mL · Spray, Metered · Nasal · Pfizer Laboratories Div Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0025-0166-08 | 00025016608 | 1 BOTTLE, SPRAY in 1 CARTON (0025-0166-08) / 8 mL in 1 BOTTLE, SPRAYMarketed from Feb 13, 1990 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Synarel
- Generic name (nonproprietary)
- nafarelin acetate
- Active ingredients
- Nafarelin acetate — 2 mg/mL
- Dosage form
- Spray, Metered
- Route
- Nasal
- Labeler
- Pfizer Laboratories Div Pfizer IncNDC labeler code 0025
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 019886
- Marketing start
- Listing expires
- Other FDA classes
- Gonadotropin Releasing Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 0025-0166_0ce07394-417b-4592-a051-8d63bdafbadaSPL ID 0ce07394-417b-4592-a051-8d63bdafbadaSPL set ID d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6RxCUI 1797878, 1797880UNII 8ENZ0QJW4H
- Pharmacologic class
- Gonadotropin Releasing Hormone Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400025016608followed by a unit qualifier and the quantityPackage 00025-0166-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usual…
Excerpt only. Read the full label for complete information.
About NDC 0025-0166
- What is NDC 0025-0166?
- 0025-0166 is the product NDC for Synarel (nafarelin acetate), Nafarelin acetate 2 mg/mL spray, metered, listed with the FDA by Pfizer Laboratories Div Pfizer Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Synarel (Nafarelin acetate).
- What is the active ingredient?
- Nafarelin acetate.
- Who is the labeler?
- Pfizer Laboratories Div Pfizer Inc, NDC labeler code 0025. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Synarel?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.